CA2451798C - Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a - Google Patents

Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a Download PDF

Info

Publication number
CA2451798C
CA2451798C CA2451798A CA2451798A CA2451798C CA 2451798 C CA2451798 C CA 2451798C CA 2451798 A CA2451798 A CA 2451798A CA 2451798 A CA2451798 A CA 2451798A CA 2451798 C CA2451798 C CA 2451798C
Authority
CA
Canada
Prior art keywords
compound
disorders
compounds
pipamperone
ht2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2451798A
Other languages
English (en)
Other versions
CA2451798A1 (fr
Inventor
Erik Buntinx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharmaNeuroBoost NV
Original Assignee
PharmaNeuroBoost NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PharmaNeuroBoost NV filed Critical PharmaNeuroBoost NV
Priority to CA2451798A priority Critical patent/CA2451798C/fr
Priority to CA 2461248 priority patent/CA2461248C/fr
Priority to CA 2487529 priority patent/CA2487529A1/fr
Priority to RSP-2010/0323A priority patent/RS51331B/en
Priority to AT04801138T priority patent/ATE464901T1/de
Priority to SI200431439T priority patent/SI1708790T1/sl
Priority to EP10159625A priority patent/EP2272514A1/fr
Priority to DK04801138.1T priority patent/DK1708790T3/da
Priority to PL04801138T priority patent/PL1708790T3/pl
Priority to PCT/BE2004/000172 priority patent/WO2005053796A1/fr
Priority to DE602004026781T priority patent/DE602004026781D1/de
Priority to PT04801138T priority patent/PT1708790E/pt
Priority to CA002547639A priority patent/CA2547639A1/fr
Priority to EP04801138A priority patent/EP1708790B1/fr
Priority to ES04801138T priority patent/ES2343962T3/es
Priority to JP2006541759A priority patent/JP4571645B2/ja
Priority to US10/580,962 priority patent/US8304431B2/en
Publication of CA2451798A1 publication Critical patent/CA2451798A1/fr
Priority to CY20101100611T priority patent/CY1111017T1/el
Priority to HR20100376T priority patent/HRP20100376T1/hr
Priority to US12/924,615 priority patent/US20110136865A1/en
Application granted granted Critical
Publication of CA2451798C publication Critical patent/CA2451798C/fr
Priority to US13/065,638 priority patent/US20110207776A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2451798A 2003-12-02 2003-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a Expired - Fee Related CA2451798C (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CA2451798A CA2451798C (fr) 2003-12-02 2003-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a
CA 2461248 CA2461248C (fr) 2003-12-02 2004-03-18 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
CA 2487529 CA2487529A1 (fr) 2003-12-02 2004-11-15 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
ES04801138T ES2343962T3 (es) 2003-12-02 2004-12-02 Uso de pipamperona y un antagonista de receptores d2 o un antagonista de serotonina/dopamina para el tratamiento de trastornos psicoticos.
SI200431439T SI1708790T1 (sl) 2003-12-02 2004-12-02 Uporaba pipamerona in d receptorskega antagonista kot serotonin dopamin antagonista za zdravljenjepsihičnih nepravilnosti
EP10159625A EP2272514A1 (fr) 2003-12-02 2004-12-02 Utilisation d'une faible dose de pipamperone et d'un deuxième agent actif dans le traitement des maladies neurodégénératives
DK04801138.1T DK1708790T3 (da) 2003-12-02 2004-12-02 Anvendelse af pipamperon af en D2-receptorantagonist eller serotonin/dopaminantagonist til behandling af psykotiske sygdomme
PL04801138T PL1708790T3 (pl) 2003-12-02 2004-12-02 Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
PCT/BE2004/000172 WO2005053796A1 (fr) 2003-12-02 2004-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
DE602004026781T DE602004026781D1 (de) 2003-12-02 2004-12-02 Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonist
RSP-2010/0323A RS51331B (en) 2003-12-02 2004-12-02 USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
CA002547639A CA2547639A1 (fr) 2003-12-02 2004-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
EP04801138A EP1708790B1 (fr) 2003-12-02 2004-12-02 Utilisation de pipamperone et d'un antagoniste des recepteurs d2 ou d'un antagoniste a la dopamine et a la serotonine pour le traitement de troubles psychotiques
AT04801138T ATE464901T1 (de) 2003-12-02 2004-12-02 Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen
JP2006541759A JP4571645B2 (ja) 2003-12-02 2004-12-02 Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
US10/580,962 US8304431B2 (en) 2003-12-02 2004-12-02 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
PT04801138T PT1708790E (pt) 2003-12-02 2004-12-02 Utilizaã†o de pipamperona e de um antagonista dos receptores d2 ou de um antagonista da dopamina e da serotonina para o tratamento de transtornos psicëticos
CY20101100611T CY1111017T1 (el) 2003-12-02 2010-07-05 Χρηση πιπαμπερονης και ενος ανταγωνιστη d-2 υποδοχεα ή ανταγωνιστη σεροτονινης/ντοπαμινης για την θεραπεια ψυχωτικων διαταραχων
HR20100376T HRP20100376T1 (hr) 2003-12-02 2010-07-06 Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja
US12/924,615 US20110136865A1 (en) 2003-12-02 2010-09-30 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US13/065,638 US20110207776A1 (en) 2003-12-02 2011-03-25 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2451798A CA2451798C (fr) 2003-12-02 2003-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a

Publications (2)

Publication Number Publication Date
CA2451798A1 CA2451798A1 (fr) 2005-06-02
CA2451798C true CA2451798C (fr) 2010-11-02

Family

ID=34596865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2451798A Expired - Fee Related CA2451798C (fr) 2003-12-02 2003-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a

Country Status (1)

Country Link
CA (1) CA2451798C (fr)

Also Published As

Publication number Publication date
CA2451798A1 (fr) 2005-06-02

Similar Documents

Publication Publication Date Title
US7855195B2 (en) Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20110172251A1 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20060211686A1 (en) Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
US6169098B1 (en) Composition and methods employing it for the treatment of 5-HT-mediated disorders
JP5684388B2 (ja) 抗精神病薬誘発性体重増加を治療するための方法
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1541197A1 (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs D4 et 5-HT2A
EP1547650A1 (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des récepteurs D4 et 5-HT2A
RU2440116C2 (ru) Фармацевтическая композиция, обладающая антипсихотической, антидепрессантной или противоэпилептической активностью, со сниженным побочным эффектом
EP1576985A1 (fr) Utilisation d'antagonistes, d'agonistes partiels ou d'agonistes inverses des recepturs D4 et 5-HT2A
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
EP2236138A1 (fr) Pipampèrone faible dose pour le traitement des troubles de l`anxiété et de l`humeur
CA2451798C (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a
EP2236157A1 (fr) Pipampérone et un agent ultérieur pour le traitement des troubles de l'humeur et de l'anxiété
CA2461248C (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
Behere et al. Clinical psychopharmacology: an update
AU6378199A (en) A new composition
RU2508106C2 (ru) Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
First-Generation PART VII Miscellaneous Systemic Drugs
ES2343962T3 (es) Uso de pipamperona y un antagonista de receptores d2 o un antagonista de serotonina/dopamina para el tratamiento de trastornos psicoticos.
WO2000015218A1 (fr) Nouvelle composition
JPH07503240A (ja) ３‐アリールインドールおよび１‐アリールインダゾール誘導体の精神病の治療のための使用
JP2002524507A (ja) 新規組成物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141202